<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008744</url>
  </required_header>
  <id_info>
    <org_study_id>00003168</org_study_id>
    <nct_id>NCT05008744</nct_id>
  </id_info>
  <brief_title>Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome</brief_title>
  <official_title>Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome (TTTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of diode laser photocoagulation of the&#xD;
      communicating vessels in twin-to- twin transfusion syndrome (TTTS) with respect to maternal,&#xD;
      fetal and neonatal outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo an intake evaluation followed by a detailed ultrasound examination to&#xD;
      rule out the presence of congenital anomalies and to assess the hemodynamic status of the&#xD;
      fetuses and any pre-existing cerebral damage. The following data will be collected, as is&#xD;
      identical to the standard of care in evaluating monochorionic twins&#xD;
&#xD;
      Maternal&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Gravidity and parity&#xD;
&#xD;
        -  BMI&#xD;
&#xD;
        -  Race/ethnicity&#xD;
&#xD;
        -  Gestational age&#xD;
&#xD;
        -  The presence of any symptoms&#xD;
&#xD;
        -  Cervical length&#xD;
&#xD;
      Fetal&#xD;
&#xD;
        -  Estimated fetal weight&#xD;
&#xD;
        -  Detailed anatomy&#xD;
&#xD;
        -  Doppler evaluation of umbilical cord, ductus venosus and middle cerebral arteries&#xD;
&#xD;
        -  Evaluation of the myocardial performance indices&#xD;
&#xD;
        -  Amniotic fluid volume&#xD;
&#xD;
        -  Placental position&#xD;
&#xD;
        -  Cord insertions&#xD;
&#xD;
      Patients will then be counseled about the risks and benefits of the procedure and will be&#xD;
      asked to sign an informed consent.&#xD;
&#xD;
      The procedure will be performed under a spinal or local anesthesia at the discretion of the&#xD;
      anesthesiologist and surgeon based upon placental position, maternal hemodynamic stability&#xD;
      and maternal anxiety and ability to cooperate. Ultrasound guidance will help to select an&#xD;
      appropriate incisional site. Under ultrasound guidance, a 2 mm skin incision will be made and&#xD;
      a 10 French Cook Check Flow valve cannula and trocar will be introduced into the amniotic&#xD;
      cavity. An amniotic fluid sample will be obtained and sent for microbiological studies. A&#xD;
      small aliquot of fluid will also be set aside for future institutional review board approved&#xD;
      studies (see detail regarding banking below).&#xD;
&#xD;
      The communicating vessels will be located endoscopically using a Storz straight or curved&#xD;
      semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission&#xD;
      of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl&#xD;
      Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating&#xD;
      channel of the endoscope. The Laser used is a Dornier Diode laser using a power of 30-40&#xD;
      Watts. At the conclusion of the anastomotic ablation, an ablation line will be created across&#xD;
      the vascular equator, effectively dichorionizing the placenta. The procedure will be&#xD;
      monitored both endoscopically and sonographically. The presence of fetal heart activity will&#xD;
      be documented at the beginning and end of the procedure. An amniodrainage of the larger sac&#xD;
      will be performed at the conclusion of the procedure to leave the amniotic fluid volume of&#xD;
      that sac at a normal level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Immediately after the surgery to discharge from the hospital after delivery</time_frame>
    <description>Survival to discharge from the nursery of affected babies</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Twin to Twin Transfusion as Antepartum Condition</condition>
  <condition>Monochorionic Diamniotic Placenta</condition>
  <arm_group>
    <arm_group_label>Patients presenting with TTTS</arm_group_label>
    <description>Pregnant persons between 16 and 36 weeks of pregnancy with a diagnosis of twin to twin transfusion syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fetoscopic laser ablation</intervention_name>
    <description>Under ultrasound guidance, a 2 mm skin incision will be made and a 10Fr Cook Check Flow valve cannula and trocar will be introduced into the amniotic cavity.&#xD;
The communicating vessels will be located endoscopically using a Storz straight or curved semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating channel of the endoscope.</description>
    <arm_group_label>Patients presenting with TTTS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Amniotic fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant persons presenting with a diagnosis of twin to twin transfusion syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single placenta (Monochorionic)&#xD;
&#xD;
          -  Polyhydramnios present in recipient twin (Greater than 8 cm maximum vertical pocket&#xD;
             below 20 weeks and greater than a 10 cm pocket for greater than 20 weeks gestational&#xD;
             age)&#xD;
&#xD;
          -  Oligohydramnios present in donor twin (Less than 2 cm maximum vertical pocket)&#xD;
&#xD;
          -  Prominent bladder in the recipient/ non-filling bladder in the donor&#xD;
&#xD;
          -  Thin dividing membrane&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to participate in the study or to be followed up&#xD;
&#xD;
          -  Presence of major congenital anomalies incompatible with survival&#xD;
&#xD;
          -  Active pre-term labor Ruptured membranes&#xD;
&#xD;
          -  Chorioamnionitis&#xD;
&#xD;
          -  Vaginal bleeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin P Walker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Childrens Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin P Walker, MD</last_name>
    <phone>206-987-3539</phone>
    <phone_ext>73539</phone_ext>
    <email>martin.walker@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Dorn, RN MN</last_name>
    <phone>206-987-4137</phone>
    <phone_ext>74137</phone_ext>
    <email>melissa.dorn@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seattle Childrens Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Martin Walker</investigator_full_name>
    <investigator_title>Co-Director Seattle Childrens Fetal Intervention and Surgery Program, Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Twin</keyword>
  <keyword>Monochorionic</keyword>
  <keyword>Fetoscopy</keyword>
  <keyword>Laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetofetal Transfusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

